Pooled Clinical Safety Analysis of CPX-351 Versus Conventional Chemotherapy in Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1728754 ◽

2020 ◽

Vol 61 (7) ◽

pp. 1728-1731

Author(s):

Raffaele Palmieri ◽

Sarah A. Buckley ◽

Megan Othus ◽

Anna B. Halpern ◽

Mary-Elizabeth M. Percival ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

High Grade ◽

Newly Diagnosed ◽

Phase 1 Study ◽

Myeloid Neoplasm ◽

PCN331 HUMANISTIC BURDEN OF NEWLY DIAGNOSED VERSUS RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Value in Health ◽

10.1016/j.jval.2019.09.526 ◽

2019 ◽

Vol 22 ◽

pp. S500

Author(s):

S. Panjabi ◽

A. Bychenkova ◽

C. McCloskey ◽

S. Nair ◽

K. Price ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽

Humanistic Burden ◽

Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old

Leukemia Research ◽

10.1016/j.leukres.2003.12.012 ◽

2004 ◽

Vol 28 (9) ◽

pp. 909-919 ◽

Cited By ~ 32

Author(s):

Simrit Parmar ◽

Lynn M Rundhaugen ◽

Larry Boehlke ◽

MaryBeth Riley ◽

Chadi Nabhan ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Arsenic Trioxide ◽

Phase Ii ◽

Myeloid Leukemia ◽

Phase Ii Trial ◽

Newly Diagnosed ◽

Secondary Leukemia ◽

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Case Medical Research ◽

10.31525/ct1-nct04047641 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

Leukemia & Lymphoma ◽

10.3109/10428194.2013.877134 ◽

2014 ◽

Vol 55 (10) ◽

pp. 2301-2304 ◽

Cited By ~ 37

Author(s):

Mark H. Kirschbaum ◽

Kenneth A. Foon ◽

Paul Frankel ◽

Christopher Ruel ◽

Bernadette Pulone ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Study ◽

The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia

Expert Opinion on Drug Safety ◽

10.1080/14740338.2021.1913120 ◽

2021 ◽

pp. 1-9

Author(s):

Giovanni Marconi ◽

Maria Benedetta Giannini ◽

Gianmarco Bagnato ◽

Giorgia Simonetti ◽

Claudio Cerchione ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Safety Profile ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽

Flt3 Inhibitors ◽

Review for "Optimizing Venetoclax Dose in Combination with Low Intensive Therapies in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: An Exposure-Response Analysis"

10.1002/hon.2646/v1/review2 ◽

2019 ◽

Keyword(s):

Acute Myeloid Leukemia ◽

Elderly Patients ◽

Myeloid Leukemia ◽

Response Analysis ◽

Newly Diagnosed ◽

Exposure Response ◽

13 / MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study.

10.26226/morressier.5b3b802cb1b87b000eced984 ◽

2018 ◽

Author(s):

Maiti Abhishek

Keyword(s):

Acute Myeloid Leukemia ◽

Phase I ◽

Myeloid Leukemia ◽

Mek Inhibitor ◽

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Case Medical Research ◽

10.31525/ct1-nct03839771 ◽

2000 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Maintenance Therapy ◽

Induction Therapy ◽

Myeloid Leukemia ◽

Intensive Chemotherapy ◽

Consolidation Therapy ◽

Newly Diagnosed ◽

Idh2 Mutation ◽

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Case Medical Research ◽

10.31525/ct1-nct03862157 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽